

CODING GUIDE

The coding information in this guide is gathered from third-party publicly available sources and is intended for reference only. Decisions regarding coding, medical necessity, and any documentation to support coverage are the responsibility of the healthcare provider and must be made considering the clinical facts, circumstances, and applicable coding rules, including the requirement to code to the highest level of specificity. Nothing in this document is intended to serve as reimbursement guidance or treatment advice, a guarantee of coverage, or a guarantee of partial or full payment. Plans, coding, and coverage parameters issued by payers, including formularies, are subject to change without notice. Actual benefits are determined by the respective plan administrators. Check each patient's coverage with the applicable insurer. AbbVie does not endorse any individual plans. Coverage does not imply safety or efficacy.

INDICATION

JUVMO is indicated for the treatment of Parkinson's disease in adults.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hypotension/Orthostatic Hypotension: Patients with Parkinson's disease (PD) may have an impaired capacity to respond to an orthostatic challenge. In clinical studies and clinical experience, dopaminergic medications appear to impair the systemic regulation of blood pressure, resulting in hypotension and/or orthostatic hypotension, especially during dose escalation. Patients with PD treated with JUVMO (tavapadon) should be monitored for signs and symptoms of hypotension/orthostatic hypotension, especially during dose escalation, and should be informed of this risk.

Impulse Control/Compulsive Behaviors: Patients may experience intense urges while on JUVMO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while on JUVMO. Consider reducing the dose or discontinuing JUVMO if a patient develops such urges.

Hallucinations and Psychotic-like Behavior: Medications for the treatment of PD, including JUVMO, can have effects on thinking and behavior. Age appears to increase the risk of hallucinations in patients taking JUVMO. The risk of hallucination may be increased when JUVMO is co-administered with strong CYP3A inhibitors during the maintenance phase. Consider the risks and benefits prior to initiating treatment with JUVMO in patients with a major psychotic disorder because of the risk of exacerbating psychosis. Consider stopping JUVMO if hallucinations or psychotic-like behaviors occur.

Please see additional Important Safety Information on the following pages.

Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/juvmo_pi.pdf) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.



Within this guide are codes you may find helpful. All coding decisions should be made by the healthcare provider based on an independent review of the patient's condition. Please note that payer policies regarding coverage vary. Check each patient's coverage with the applicable insurer.

Diagnosis Codes for Parkinson's Disease

ICD-10-CM Code	Diagnosis
G20.A	Parkinson's disease without dyskinesia
G20.A1	Parkinson's disease without dyskinesia, without mention of fluctuations
G20.A2	Parkinson's disease without dyskinesia, with fluctuations
G20.B	Parkinson's disease with dyskinesia
G20.B1	Parkinson's disease with dyskinesia, without mention of fluctuations
G20.B2	Parkinson's disease with dyskinesia, with fluctuations

NDC Codes

Dosage Form	Code
Titraton Pack (40-day supply)	0074-6090-40
5 mg tablets / bottle of 30	0074-6105-30
10 mg tablets / bottle of 30	0074-6210-30
15 mg tablets / bottle of 30	0074-6315-30



Keep in mind: Incorrect medical coding can result in a payment denial or delay, which can impact the patient's treatment journey.



For more coding support, reach out to your JUVMO Field Reimbursement Manager (FRM). They can help answer any questions you may have.

Codes are for informational purposes only and are not intended to suggest the use of any drug that is inconsistent with FDA approval, or to function as reimbursement or legal advice. Providers should verify codes with third-party payers. The codes shown are only suggestions. The codes you may need can vary by patient.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Dyskinesia: JUVMO may cause or exacerbate pre-existing dyskinesia. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.

Adverse Reactions

The most common adverse reactions ($\geq 5\%$) for JUVMO without levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.

The most common adverse reactions ($\geq 5\%$) for JUVMO with levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Please see additional Important Safety Information throughout.

Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/juvmo_pi.pdf) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.

GET TO KNOW YOUR FIELD REIMBURSEMENT MANAGER (FRM)

PROVIDING OFFICE EDUCATION TO HELP NAVIGATE ACCESS AND COVERAGE DETERMINATION PROCESSES

Your FRM is a primary point of contact for access and coverage support and can provide:



Guidance on payer prior authorization, documentation, and exception or appeals processes to help you help your patients access their prescribed therapy



Information on financial support options which may be available for your patients, when insurance coverage is still being established or access challenges arise



Educational resources and tools related to access and reimbursement



Information on government and commercial plans at the local, national, and program levels



For more information or assistance with any access or reimbursement issue, contact your JUVMO FRM.

FRM support is for educational purposes only, subject to change, and not intended to serve as reimbursement guidance or treatment advice, a guarantee of coverage, or a guarantee of partial or full payment.

IMPORTANT SAFETY INFORMATION (cont'd)

Drug Interactions

Strong CYP3A Inducers: Avoid use with JUVMO. **Strong and moderate CYP3A inhibitors:** avoid use with JUVMO during titration; JUVMO dosage modification is recommended during maintenance. **Moderate CYP3A Inducers:** JUVMO dosage modification is recommended during titration and maintenance. **Consult the full Prescribing Information for JUVMO** for more information on drug interactions and recommended dosage modifications.

Dosage Forms and Strengths

JUVMO is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see accompanying full [Prescribing Information](#) or visit https://www.rxabbvie.com/pdf/juvmo_pi.pdf.

abbvie